Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl

Published:2018-07-11 Issue:15 Volume:61 Page:6869-6891
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Iwamura Ryo¹^ORCID,Tanaka Masayuki¹,Okanari Eiji¹,Kirihara Tomoko²,Odani-Kawabata Noriko²,Shams Naveed²³,Yoneda Kenji¹

Affiliation:

1. Pharmaceuticals Research Laboratory, UBE Industries, Ltd., 1978-5 Kogushi, Ube, Yamaguchi 755-8633, Japan

2. R&D Division, Santen Pharmaceutical Co., Ltd., Grand Front Osaka Tower A 4-20, Ofukacho, Kita-ku, Osaka 530-8552, Japan

3. R&D Division, Santen Inc., 6401 Hollis Street, Suite 125, Emeryville, California 94608, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b00808

Reference43 articles.

1. Protective Effects of Inhaled PGE2on Allergen-induced Airway Responses and Airway Inflammation

2. The Role of Prostaglandin E Receptor Subtypes (EP1, EP2, EP3, and EP4) in Bone Resorption: An Analysis Using Specific Agonists for the Respective EPs

3. Topical Prostaglandin E2 Effects on Normal Human Intraocular Pressure

4. Prostaglandin E Receptors

5. Prostanoid Receptor EP2 as a Therapeutic Target

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect;European Journal of Medicinal Chemistry;2024-11

2. QSAR and docking based lead optimization of nitrogen heterocycles for enhanced prostaglandin EP2 receptor agonistic potency;Chemical Physics Impact;2024-06

3. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug;Current Opinion in Pharmacology;2024-02

4. Novel Carbonic Anhydrase Inhibitors with Dual-Tail Core Sulfonamide Show Potent and Lasting Effects for Glaucoma Therapy;Journal of Medicinal Chemistry;2024-01-24

5. Prodrugs as empowering tools in drug discovery and development: recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates;Chemical Society Reviews;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3